3 years ago

Dxcover Secures £9.7M for Liquid Biopsy Cancer Detection Platform

  • Dxcover, a Glasgow-based liquid biopsy company, has raised £9.7M in Series A funding from various investors to support the development of its platform for detecting early-stage cancers.

      • ProblemHealthcare

      "Current cancer detection methods are often invasive, expensive, and only effective in later stages, leading to delayed treatment and lower survival rates."

      Solution

      "Dxcover develops a blood test using infrared spectroscopy and AI to detect multiple cancers at the earliest stages, allowing for timely interventions and improved patient outcomes."

      Covered on